
President Trump’s drug pricing order has triggered uncertainty in the pharma sector. Nomura warns Sun Pharma could be hit hardest…
US President Trump’s move to cut drug prices by 30–80% may severely impact Indian pharma exports and profitability, especially in…
Indian markets steady despite border tensions; Sensex and Nifty end slightly up. Discover top gainers and laggards of the day!
Markets flat; Nifty below 23,300 as auto, pharma slip. Gensol down 5%. Explore the latest market shifts now!
Pharma stocks surge as Trump’s tariff exemption boosts sector morale. Dive into this bullish trend today!
Indian markets end flat amid global jitters; IndusInd Bank falls 27%, Trent leads gainers. Explore market trends!
Sun Pharma surges 3% on Checkpoint Therapeutics acquisition; Motilal Oswal maintains ‘Buy’ with 22% upside potential. Read more!
Stocks to watch today, March 11: GIFT Nifty was trading lower at 22,363, which indicates a negative start for domestic…
For the nine-month period ending September 2024, Checkpoint reported $0.04 million in revenue and a net loss of $27.3 million.
Sun Pharmaceutical shares have delivered impressive gains across multiple time frames, reflecting strong investor interest. Over the past three months,…
The company’s EBITDA stood at Rs. 3939.0 crore (including other operating revenues), up 23.9 percent, with resulting EBITDA margin of…
Under the terms of the agreement, Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun.
Sun Pharma described the investment as strategic, noting it will gain exclusive rights to market and distribute Pharmazz’s drug, Sovateltide,…
Sun Pharma Q1 Results 2024: Sun Pharmaceutical Industries Ltd. consolidated total revenue from operations was Rs 12,652.75 crore, up from…
Alopecia areata is a common autoimmune disease in which hair loss is thought to occur due to the collapse of…
Sun Pharma has been the majority shareholder of Taro since 2010.
Sun Pharma posted revenue from operations at Rs 11,982.90 crore, up 9.6 per cent as against Rs 10,930.67 crore during…
SPARC plans to complete the full analysis of clinical outcomes and correlative biomarker data in the coming months, it added.